# **Supplementary Information**

# Mathematical modeling of vaccination rollout and NPIs lifting on COVID-19 transmission with VOC: a case study in Toronto, Canada

Elena Aruffo<sup>1,2\*</sup>, Pei Yuan<sup>1,2\*</sup>, Yi Tan<sup>1,2,\*</sup>, Evgenia Gatov<sup>3</sup>, Iain Moyles<sup>1,2</sup>, Jacques Bélair<sup>1,5</sup>, James Watmough<sup>1,6</sup>, Sarah Collier<sup>3</sup>, Julien Arino1<sup>1,4</sup>, Huaiping Zhu<sup>1,2†</sup>

<sup>1</sup> Centre for Diseases Modeling (CDM), York University, Toronto, Canada

<sup>2</sup> Department of Mathematics and Statistics, York University, Toronto, Canada

<sup>3</sup> Toronto Public Health, City of Toronto, Toronto, ON, Canada.

<sup>4</sup> Department of Mathematics, University of Manitoba, Winnipeg, Manitoba, Canada

<sup>5</sup> Département de Mathématiques et de Statistique, Université de Montréal, Montréal, Québec, Canada

<sup>6</sup> Department of Mathematics and Statistics, University of New Brunswick, Fredericton, New Brunswick, Canada

\* Co-first authors made the same contributions.

<sup>†</sup> Corresponding Author: <u>huaiping@yorku.ca</u>,

4700 Keele Street, Toronto, Ontario, Canada, M3J1P3

# Model

The system of ODEs describing the dynamic is given by:

$$\begin{split} S_{i}^{\prime} &= -\lambda_{s_{i}} - \phi_{i} S_{i} \left\{ \left( 1 - b(t) \right) \left[ \beta^{o} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] \right\} + \omega_{1} V_{1i} + \omega_{2} V_{2i} \\ &= b(t) \left[ \beta^{N} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] \right\} + \omega_{1} V_{1i} + \omega_{2} V_{2i} \\ &= i = \phi_{i} S_{i} \left\{ \left( 1 - b(t) \right) \left[ \beta^{o} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] - b(t) \left[ \beta^{N} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] \right\} \\ &+ \phi_{i} V_{1i} (1 - \epsilon_{1i}) \left\{ \left( 1 - b(t) \right) \left[ \beta^{o} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] \right\} - (1 - b(t)) \alpha^{o} E_{i} - b(t) \alpha^{N} E_{i} \\ &- b(t) \left[ \beta^{N} \sum_{j}^{5} c_{ij}(A_{i} + \xi I_{m_{i}}) \right] \right\} - (1 - b(t)) \gamma^{o}_{aR_{i}} A_{i} \\ &- b(t) \gamma^{N}_{aR_{i}} A_{i} \\ I'_{m_{i}} &= \rho (1 - b(t)) \alpha^{o} E_{i} + \rho b(t) \alpha^{N} E_{i} - (1 - b(t)) \gamma^{o}_{aR_{i}} A_{i} \\ &- b(t) \gamma^{N}_{aR_{i}} A_{i} \\ I'_{m_{i}} &= \rho (1 - b(t)) \alpha^{o} E_{i} + \rho b(t) \alpha^{N} E_{i} - (1 - b(t)) \gamma^{o}_{mR_{i}} I_{m_{i}} \\ &- (1 - b(t)) \gamma^{o}_{mR_{i}} I_{m_{i}} - b(t) \gamma^{N}_{mR_{i}} I_{m_{i}} \\ &- (1 - b(t)) \gamma^{o}_{aR_{i}} A_{i} + b(t) \gamma^{N}_{mR_{i}} I_{m_{i}} \\ H_{i}^{\prime} &= (1 - b(t)) \mu^{o}_{H_{i}} H_{i} + b(t) \gamma^{N}_{H_{i}} H_{i} \\ D_{i}^{\prime^{o}} &= (1 - b(t)) \gamma^{o}_{aR_{i}} A_{i} + (1 - b(t)) \gamma^{O}_{mR_{i}} A_{i} + (1 - b(t)) \gamma^{O}_{mR_{i}} I_{m_{i}} + b(t) \gamma^{N}_{mR_{i}} I_{m_{i}} \\ &+ (1 - b(t)) \gamma^{O}_{aR_{i}} A_{i} + b(t) \gamma^{N}_{mR_{i}} H_{i} \\ V_{1i} &= \lambda_{s_{i}} - \phi_{i} V_{1i} (1 - \epsilon_{1}) \left\{ (1 - b(t)) \left[ \beta^{o} \sum_{j}^{5} c_{ij} (A_{i} + \xi I_{m_{i}}) \right] \\ &- b(t) \left[ \beta^{N} \sum_{j}^{5} c_{ij} (A_{i} + \xi I_{m_{i}}) \right] \right\} - \sigma \epsilon_{2i} V_{1i} - \omega_{1} V_{1i} \\ V_{2i} &= \sigma \epsilon_{2i} V_{1i} - \omega_{2} V_{2i} \end{aligned}$$

For  $i \in \{1,2,3,4,5,6\}$ , where  $\beta^N = \zeta \beta^o$ .

The list of variables and assumptions is given in Table SI1.

Variable	Definition							
S <sub>i</sub>	Susceptible individuals in age group i							
Li	Latently infected individuals in age group i							
A <sub>i</sub>	Asymptomatic individuals in age group i							
I <sub>mi</sub>	Symptomatic (mild) individuals in age group i							
H <sub>i</sub>	Hospitalized individuals in age group i							
D <sub>i</sub>	Deceased individuals in age group i							
R <sub>i</sub>	Recovered individuals in age group i							
V <sub>1i</sub>	Vaccinated individuals in age group i (first dose)							
V <sub>2i</sub>	Vaccinated individuals in age group i (second dose)							
$i \in \{1,2,3,4,5,6\}$	Age groups: 0-9,10- 19, 20-39, 40-59, 60-79, 80+ years respectively							
Assumptions								
1. Only susceptible	individuals, aged 10 years and older, will receive the vaccine							
2. Immunity follow	s two steps: partial (receiving one dose) and full (receiving two doses)							
3. The vaccine effic	cacy is age dependent (higher for teenagers and adults, lower for elderly)							
4. The vaccine effic	cacy is the same against wildtype variant and VOC							
5. The second dose following the sug	is given after 112 days (in some predictive scenarios after 50 or 21 days), ggestion announced by the Government of Ontario in March 2021 [33]							
6. Immunity wanes days	from one dose of vaccine after 120 days and from two doses after 365							
7. We assume that vaccination proce	the coverages in Table 2 are reached by June 14, 2021, and continue the ess until 80% of the total population is vaccinated							
8. We assume that a	all non-wild type cases belong to B.1.1.7							
<ol> <li>VOC and wildtype are both included in the transmission process, assuming that proportion of cases from VOC increases by time, following a sigmoidal function</li> </ol>								
10. The transmission	10. The transmission from VOC is assumed to be 1.5 higher than the original variant							
11. Vaccine reduces susceptibility. Partially vaccinated people can become infected and infectious if the vaccine is not efficient								
12. Only individuals	12. Only individuals hospitalized might die from the infection							

Table SI1: Table of the model's variables and assumptions

Table SI2: Table of	f model parameters
---------------------	--------------------

Parameter	Definition	Value	Ref.
$\lambda_{s_i}$	Average daily vaccine doses given at age group i	daily doses from data	[38]
$\phi_i$	Susceptibility		[39]
	for age group i	0.34 0.34 1 1 1.67 1.67	
c <sub>ij</sub>	Contacts per day		
	Reduction	0.650043 Phase I	Estim
		0.759924 Phase II	ateu
		0.665048 Phase III	
		0.77 Phase IV	
β	Probability of transmission	2.30E-07	Estim ated
ζ	Increase in transmission from VOC	1.5	Assum ed [17,18, 19,20]
ξ	Proportion of mild cases not adhering to self- isolation rule	0.20002	Estim ated
α <sup>0,N</sup>	average time in latent period	1/4 days-1	[40,41] (assu med for VOC)
ρ	Proportion of symptomatic individuals	0.8	[42]
$\gamma^{O,N}_{aR_i}$	Recovery rate from asymptomatic infection	0.16 days-1	[43]
$\gamma^o_{H_i}$	Hospitalization	0.0029 0.0005 0.0027 0.0108 0.0458 Phase I	Estim
	rate of individuals in	0.0024 0.0020 0.0047 0.0113 0.0475 Phase II	_ ated
	group I, infected	0.1194	4
	with old variant	0.1371	
		0.0014 0.0005 0.0034 0.0101 0.0327 Phase IV 0.0773	
$\gamma^N_{H_i}$		0 0 0 0 0.2550 0.1133 Phase I	+

	Hospitalization	0.0027	0.0019 0.00	066 0.0179	0.0911	Phase	II	Estim
	rate of	0.0010	0.0014 0.00	070 0.0247	0.0708	Phase	III	ated
	group L infected		0.1823					
	with VOC	0.0019	0.0009 0.00	0.0121	0.0426	Phase	IV	
240	Pocovery rate of	0.0991	0.1204	992 0.0968	0.0865	Phase	T	Coloul
Υ <sub>mRi</sub>	individuals in	0.0771	0.0704	//2 0.0/00	0.0005	Thase	· 1	ated
	group L mildly	0.0993	0.0994 0.09	0.0967	0.0860	Phase	II	attu
	infected with old	0.000 7	0.0649					_
	variant	0.0995	0.0996 0.09	0.0955	0.0840	Phase	: 111	
		0.0996	0.0998 0.09	90 0.0970	0.0902	Phase	IV	
			0.0768					
$\gamma^N_{mR_i}$	Recovery rate of individuals in	0.1000	0.1000 0.10 0.0667	00 0.1000	0.0250	Phase	I	Calcul ated
	group I, mildly	0.0992	0.0994 0.09 0.0473	981 0.0947	0.0732	Phase	II	
	VOC	0.0997	0.0996 0.09 0.0479	980 0.0929	0.0798	Phase	III	
		0.0994	0.0997 0.09 0.0621	983 0.0964	0.0872	Phase	IV	
$\mu_{H_{i}}^{O}$	Mortality rate	0 0	0.0001 0.00	0.0143	8 0.0834	Phase	١	Estim
• 111	from old variant	0 0	0.0001 0.00	0.012 0.0124	0.0522	Phase	I	ated
		$\begin{array}{c} 0 & 0 \\ 0 & 0 \end{array}$	0.0005 0.00	0.0077	0.0407	Phase		
$\mu^{N}$	Mortality rate	0 0	$\frac{0}{0}$ 0.0003	0.0007	0.0102	Phase	I I	Estim
$\mu_{H_i}$	from VOC	0 0	0.0005 0.00	0.0238	0.1336	Phase	II	ated
		0 0	0.0002 0.00	010 0.0092	0.0600	Phase	III	
0	Decovery rate of	0 0	0 0 0 0.00 0 1200 0 12	$\frac{000}{000} 0.0129$	)	Phase		Ectim
$\gamma_{HR_i}$	hospitalized	0.1200	0.0972		0.1101	Thase	- 1	ated
	group I, mildly	0.1800	0.1800 0.18 0.1532	300 0.1794	0.1736	Phase	e II	
	infected with old variant	0.1800	0.1800 0.17 0.1607	798 0.1796	6 0.1764	Phase	III	
		0.1300	0.1300 0.13 0.1272	300 0.1299	0.1298	Phase	IV	
$\gamma^N_{HR_i}$	Recovery rate of hospitalized	0.1200	0.1200 0.12 0.1200	200 0.1200	0.0900	Phase	I	Estim ated
	individuals in group I, mildly	0.1800	0.1800 0.17 0.1113	798 0.1791	0.1678	Phase	e II	
	infected with VOC	0.1800	0.1800 0.17 0.1516	799 0.1795	5 0.1756	Phase	III	
		0.1300	0.1300 0.13 0.1264	300 0.1300	0.1296	Phase	IV	
$\epsilon_{1_i}$	Efficacy first					·		Assum
	dose for age	0	0.8	0.8	0.8	0.7	0.7	ed [44]
	group i	reduced	by 0.1 in low	er efficacy	scenario			
$\epsilon_{2_i}$	Efficacy second			1				Assum
	dose for age	0	0.9	0.9	0.9	0.8	0.8	ed [44]
	group 1	reduced	by 0.1 in low	er efficacy s	scenario			

σ	Average time to	1/112 days-1	[33]				
	receive second						
	dose						
ω <sub>1</sub>	Average time to	1/120 days-1	Assum				
-	wane immunity		ed				
	after first dose						
ω2	Average time to	1/365 days <sup>-1</sup>	Assum				
_	wane immunity		ed				
	after second						
	dose						
$S_{0i}$	Susceptible		Calcul				
с <sub>1</sub>	individuals in	283648 280541 901570 832208 546916 150982	ated				
	age group I						
	(initial value)						
$E_{0i}$	Exposed		Calcul				
Ĺ	individuals in		ated				
	age group I	Old         158         301         1528         9         553         264					
	(initial value)	VOC         0         0         1         2         2         1					
$A_{0i}$	Asymptomatic		Calcul				
C C	individuals in	Old 46 78 340 300 152 61	ated				
	age group I	VOC 0 0 0 0 0 1					
	(initial value)						
$I_{m0_i}$	Symptomatic		Calcul				
	individuals in	Old 34	ated				
	age group I	0 529 2378 1936 877 318					
	(initial value)	$\begin{bmatrix} \mathbf{V} \mathbf{O} \\ \mathbf{C} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix} \end{bmatrix} \begin{bmatrix} 0 \\ 0 \end{bmatrix}$					
$H_{0i}$	Hospitalized		Calcul				
01	individuals in	Old 4 4 44 121 236 208	ated				
	age group I	VOC 0 0 0 0 0 0					
	(initial value)						
$D_{0i}$	Deceased		Calcul				
- L	individuals in	Old 1 0 4 79 527 1351	ated				
	age group I	VOC 0 0 0 0 0 0					
	(initial value)						
$R_{0i}$	Recovered	Old 2735 4637 21635 17060 8010 3588	Calcul				
	individuals in	VOC 000000	ated				
	age group I						
	(initial value)						
SENSITIVI	TY ANALYSIS P	ARAMETERS					
PARAMET	ER	DEFINITION RANGE (	uniform				
		distribution)					
	σ	Rate at which second dose is [1/112, 1/21]					
		distributed					
	$\lambda_2$	Daily doses age group 10-19 [500, 2719]					
	$\lambda_3$	Daily doses age group 20-39         [1624, 8559]					
	$\lambda_4$	Daily doses age group 40-59         [2312, 8714]					
	$\lambda_5$	Daily doses age group 60-79         [599, 2702]					
	Ac	Daily doses age group 80+ [319, 900]					

#### **Proportion of VOC cases**

To capture the increasing trend of cases from VOC, we defined a time-dependent function (b(t)) following a sigmoid function. Fig. A1 shows the proportion of cases from VOC from data (red circles) and the function used to reproduce their trend (blue curve). According to data up to May 19, 2021 the proportion of cases from VOC in Toronto reached a maximum of 0.8 by May 11, 2021. Hence, we consider 80% to be the maximum of cases generated by the new variant.



**Fig. SI1:** Sigmoidal function describing the growth of proportion of cases from VOC in Toronto. Scatter plot represents the proportion of VOC cases in Toronto from December 28, 2020 to May 11, 2021.

#### Data fitting

To calibrate the model's parameters, we employed the Least Squared Method (LSM) using cumulative and daily cases and deaths, and hospitalizations (Figure SI2)



**Figure SI2:** Parameters' calibration using Least Square Method. We used cumulative and daily cases and deaths, and hospitalizations between December 28, 2020 and May 19, 2021.

## Permutations of model's analysis

All the scenarios used for the projections are shown in Figure SI3. Each scenario is described by taking one element in each column.



**Figure SI3:** Outward-facing model coverages and base line for model's analysis. All these coverages are reached by June 14, 2021. In brackets, we report the daily doses. Each scenario is described by taking one element in each column.

#### Contact matrix

We used the total contact matrix from a recent Canadian study [32]. However, the age groups used in this study were defined by a 5-year band from 0 to 80+. Our model is using larger age groups, then it was necessary to aggregate the original contact matrix in less groups.

Let's define  $P_j$  the population size of age group  $j \in \{1,2,3, ..., 17\}$ , where 1 = 0 - 4 years, 2 = 5 - 9 years, ..., 17 = 80 + years. To better approximate the contact rates, we calculated, from the original 17x17 matrix  $(M_{ij})$ , the total contacts that an age group has with all the other age groups. To obtain this, we multiplied all the age groups by their own population size, i.e.  $m_{ij} \times P_j$ . Then, to aggregate some age groups, we averaged the total contacts as follows:

- For same ages belonging to new aggregation: we summed up the diagonal entries of the submatrix related to the age groups to aggregate and the average of the mixed contacts  $(\hat{c}_{ii} = \sum m_{ii} + \sum \frac{m_{ij} + m_{ji}}{2})$ . For example, the new contact of the aggregated group 0-9, given by group 1 and 2, will be  $m_{11} + m_{22} + \frac{m_{12} + m_{21}}{2}$
- For different ages aggregation: we summed up the average of the mixed contacts  $(\hat{c}_{ij} = \sum \frac{m_{ij} + m_{ji}}{2})$ . For example, the new contact of the aggregated group 0-9 and 10-19, given by group 1, 2, 3 and 4, will be  $\frac{m_{13} + m_{31}}{2} + \frac{m_{14} + m_{41}}{2} + \frac{m_{23} + m_{32}}{2} + \frac{m_{24} + m_{42}}{2}$

Once we reduced the total contacts into a smaller matrix, we re-parametrized each entry of the new age group dividing the obtained contacts by the population size of the aggregate age group (i.e.,  $c_{ij} = \hat{c}_{ij} / \sum P_i$ ). Table A2 represents the compacted matrix.

#### Table SI3: Contact matrix

		Age participants									
		0-9	10-19	20-39	40-59	60-79	80+				
	0-9	2.59	0.54	0.51	0.67	0.21	0.04				
Age contacts	10-19	0.56	3.13	0.66	0.86	0.21	0.10				
	20-39	1.88	2.35	2.52	3.06	1.29	0.65				
	40-59	1.88	2.33	2.33	2.10	1.50	1.10				
	60-79	0.40	0.39	0.66	1.00	1.25	1.04				
	80+	0.02	0.05	0.09	0.20	0.28	0.58				

#### **RESULTS**

#### Reproduction number $R_c$

Figure SI4: Contour plots of R<sub>c</sub> assuming that the following coverages reached for age groups 10-19, 60-79 and 80+ years are 20%, 80%, and 90%, respectively, when the NPIs level reopening is (A) partial, (B) total an (C) pre-pandemic. As expected, as the vaccination coverage increases, the values of the reproduction number decrease. Also, we observe that with the lowest reopening level, to reduce the reproduction number below 1, it is sufficient to vaccinate age groups 20-39 and 40-59 years above 60% and 62%, respectively. On the other hand, a relaxation of NPIs and increase in contacts as in NPIs partial reopening, the R<sub>c</sub> will always be greater than 1. Similar results, but higher  $R_c$ , are shown with NPIs pre-pandemic reopening (C).



С

# **Projections**

**Table SI4** : Percentage change of cumulative deaths with respect to the baseline with respect to the base line NPIs no reopening in SI Figure SI3 with partial, total and pre-pandemic reopening in August and September, when age groups 10-19, 60-79 and 80+ reached coverages 20%, 80%, 90%. The second dose is given at a rate of 1/112 days<sup>-1</sup>.

Projected percentage change of <u>cumulative cases</u> with respect to the base line NPIs no reopening in SI Figure SI3							
	If reopen	in AUGUS	Т				
		20-39 year	rs				
		coverage	by June 14	, 2021			
		60%			80%		
NPI's Level of reopening		Partial	Total	Pre- pandemic	Partial	Total	Pre- pandemic
40-59 years	70%	4.15	202	1178	1.51	71.34	1175
coverage by June 14,	80%	2.75	138.4	1175	0.93	45	1169
2021	90%	1.77	88	1169	0.49	27.6	1159
		In reopen in SEPTEMBER					
		20-39 years coverage by June 14, 2021					
		60%			80%		
NPI's Level of reopening		Partial	Total	Pre- pandemic	Partial	Total	Pre- pandemic
40-59 years	70%	-1.5	33.4	1167	-1.58	10.67	1058
coverage by June 14,	80%	-1.55	20.8	1130	-1.61	6.3	977
2021	90%	-1.59	12.36	1075	-1.64	3.7	871

**Figure SI5:** Hospitalizations with partial reopening in August (A) if 40-59 is vaccinated 70%-00%, 20-39 60%, 80% and 10-19, 60-79 and 80+ reached coverages 20%, 80%, 90%. The second dose is given at a rate of  $1/112 \text{ days}^{-1}$ .



**Table SI5:** Percentage change of cumulative cases and deaths with respect to the baseline with respect to the base line NPIs no reopening in SI Figure SI3, reducing efficacy by 10%, with partial, total and pre-pandemic reopening when age groups 10-19, 60-79 and 80+ reached coverages 20%, 80%, 90%.

Projected percentage change of <u>cumulative deaths</u> with respect to the base line NPIs no reopening in SI Figure SI3 with reopening in September and efficacy reduced by 10%								
		20-39 year coverage l	rs by June 14	4, 2021				
		60%			80%			
NPI's Level of reopening		Partial	Total	Pre- pandemic	Partial	Total	Pre- pandemic	
40-59 years	70%	-1.51	48.56	1220	-1.58	18.58	1152	
coverage by June	80%	-1.55	32.12	1192	-1.61	12.27	1100	
14, 2021	90%	-1.59	21.6	1160	-1.63	7.54	1017	

**Table SI6**: Percentage change of cumulative cases and deaths with respect to the base line NPIs no reopening in SI Figure SI3 with partial, total and pre-pandemic reopening in September and second dose given after 21 or 50 days. Age groups 10-19, 60-79 and 80+ are assumed to reach coverages 20%, 80%, 90% by mid June. Par.= partial; Tot.= total; Pre-pan.= pre-pandemic..

Projected percentage change of <u>cumulative deaths</u> with respect to the base line NPIs no reopening in SI Figure SI3 with reopening in September

21 days Between dose 1 and dose 2							50 days Between dose 1 and dose 2						
20-39 years20coverage by June 14, 20210					20-39 years coverage by June 14, 2021								
		60%			80%			60%			80%		
NPI's Level of reopening		Par.	Tot.	Pre- pan.	Par.	Tot.	Pre- pan.	Par.	Tot.	Pre- pan.	Par	Tot.	Pre- pan.
40-59 vears	70%	 1.76	3.8	719	- 1.81	0.30	370	-1.61	11.8	942	- 1.67	2.8	722
coverage by June 14, 2021	80%	-1.8	1.64	577	- 1.83	-0.21	216	-1.65	6.76	868	-1.7	1.32	567
	90%	- 1.82	0.47	414	- 1.85	-0.48	110	-1.68	3.54	759	- 1.72	0.52	400

**Figure SI6:** Hospitalizations with total reopening in September if 40-59 is vaccinated 70%-00%, 20-39 60%, 80% and 10-19, 60-79 and 80+ reached coverages 20%, 80%, 90% and if the second dose is given at a rate of (A)  $1/21 \text{ days}^{-1}$  or (B)  $1/50 \text{ days}^{-1}$ .



### Sensitivity Analysis

Using the Latin Hypercube Sampling/Partial Rank Correlation Coefficient (*LHS/PRCC*) we conducted sensitivity analysis on the parameters related to vaccination, such as level of coverage, waning immunity, minimum time to reach a certain level of vaccination, as well as infection-related parameters.

**Table SI7:** PRCC on cumulative cases and deaths.

SENSITIVITY ANALYSIS									
PARAMETERS	DEFINITION	PRCC							
		CASES	DEATHS	HOSPITALIZATION (50 days after reopening in June)					
σ	Rate at which second dose is distributed	-0.9503	-0.9503	-0.9739					
$\lambda_2$	Daily doses age group 10- 19	-0.08731	-0.08731	-0.05824					
$\lambda_3$	Daily doses age group 20- 39	-0.8041	-0.8041	-0.862					
$\lambda_4$	Daily doses age group 40- 59	-0.7653	-0.7653	-0.8558					
$\lambda_5$	Daily doses age group 60- 79	-0.163	-0.163	-0.3133					
$\lambda_6$	Daily doses age group 80+	0.02592	0.02592	-0.01986					

Table SI7 shows the PRCCs of the sampled parameters  $\lambda_i$ ,  $i \in \{2,3,4,5,6\}$ , and  $\sigma$ , the daily doses in age group i, and the rate of receiving the second dose, respectively, on the cumulative cases and deaths. We observe that the age groups 3 and 4, namely, 20-39 and 40-59 years present the highest PRCC among the daily doses, suggesting that an increased vaccine coverage of these age groups leads to the largest reduction in cases and deaths. Moreover,  $\sigma$  is negatively correlated to cases and deaths, suggesting that if this rate is small, hence the time between doses is longer, cases and deaths will increase. Similar results are visible for the hospitalizations reported 50 days after reopening in June.